Mergers & Acquisitions ·
Viatris agrees to acquire Pacira BioSciences for $36.50 per share in cash
VTRSViatris Inc
Viatris Inc. entered into a definitive Agreement and Plan of Merger with Pacira BioSciences, Inc., agreeing to acquire all outstanding shares of Pacira for $36.50 per share in cash, representing an aggregate equity value of approximately $1.65 billion. Viatris will commence a tender offer for the shares, followed by a second-step merger if necessary. The transaction is expected to close by the end of 2026 and is anticipated to be immediately accretive to Viatris' financial guidance metrics. Pacira brings two high-margin, patent-protected non-opioid pain therapies, EXPAREL and ZILRETTA, which generated approximately $746 million in revenue over the last twelve months ended June 30, 2026. Viatris Inc. is a global healthcare company that develops, manufactures, and markets generic, value-added, established brand, and innovative medicines.